| |
 |
Chaoui D, Levy V, Vekhoff A, Santenac S, Bardin C, Rousselot P, Morariu R, Legrand O, Robin JP, Chast F, Marie JP. [Etude clinique et pharmacocinétique de phase I-II utilisant l'homoharringtonine hemi-synthétique (HHT, Myélostat®) chez des patients avec leucémie aiguë myéloïde (LAM) en rechute ou réfractaires]. Hematologie, Mars 2004 (abstr. # 07-04) |
| |
|
|
Maloisel F, Rousselot P, Zamfir A, Koumarianou A, Dufour P. Subcutaneous homoharringtonine (HHT) in combination with imatinib mesylate (STI571) in patients with STI571-resistant chronic myelogenous leukemia (CML). Abstract #0587 presented at the 2003 European Haematology annual meeting, Lyon, France. |
| |
|
|
Burton CH, Ranger A, Nadal E, Avery S, Nathan I, Apperley JF, Goldman JM, Marin D. Semi-Synthetic Homoharringtonine (Myelostat©) for Chronic Myeloid Leukemia in Accelerated Phase after Imatinib Failure. Abstract # 3380 presented at the 2003 American Society of Hematology annual meeting, San Diego. |
| |
|
|
Le Dieu R, Bua M, Andreasson C, Olavarria E, Goldman JM, Apperley JF, Marin D. Homoharringtonine in Combination with Imatinib for Patients with CML Who Have Achieved Partial or Complete Cytogenetic Responses. Abstract presented at the 2004 American Society of Hematology annual meeting, San Diego. |
| |
|
|
Marin D, Kaeda JS, Andreasson C, Saunders SM, Bua M, Olavarria E, Goldman JM, Apperley JF. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005 May 1;103(9):1850-1855 |
| |
|
|
Back to publications choice 
